Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).
Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study).
复制标题
专家 HIV 1 型基因型解释的准确性、精密度和一致性：国际比较（GUESS 研究）。
DOI：
10.1086/430706
复制
发表时间：
2005
期刊：
影响因子：
--
通讯作者：
Kuritzkes,Daniel
中科院分区：
文献类型：
--
作者：
Zolopa,AndrewR;Lazzeroni,LauraC;Rinehart,Alex;Vezinet,FrançoiseBrun;Clavel,François;Collier,Ann;Conway,Brian;Gulick,RoyM;Holodniy,Mark;Perno,Carlo-Frederico;Shafer,RobertW;Richman,DouglasD;Wainberg,MarkA;Kuritzkes,Daniel
背景。耐药性检测被认为是艾滋病毒医学中的护理标准，但基因型检测没有标准解释系统。我们试图确定专家组在解释复杂基因型方面存在多少共识。方法。临床样本的基因型被发送给由 12 名耐药专家组成的国际小组。使用抗病毒图对这些临床分离株进行表型敏感性测试。专家预测了表型倍数变化类别（<2.5倍变化、2.5-4.0倍变化、>4.0-7.0倍变化、>7.0-10倍变化、>10-20倍变化或>20倍变化），并预测了16种抗逆转录病毒药物中每种药物的预期药物活性。还要求专家根据基因型结果提出治疗建议。专家们在 44% 的时间内正确预测了确切的表型倍数变化类别，但它们因抗逆转录病毒药物的不同而存在很大差异（范围为 25%–74%）。拉米夫定 (74%) 和非核苷类逆转录酶抑制剂 (66%–69%) 的准确度最高。专家普遍预测，对其余核苷逆转录酶抑制剂的耐药性水平高于表型测试发现的水平。根据药物的不同，专家之间预测表型倍数变化类别的一致性差异很大（一致性中位数为 42% [范围为 28%–74%]）；在预测预期药物活性时观察到相同的模式（中位一致性，45% [范围，32%–87%]）。专家们在中位数为 79% 的情况下就治疗建议达成一致，并且随着时间的推移，经过盲法重新测试，建议是一致的。结论。尽管根据基因型预测表型的能力因个体抗逆转录病毒药物而异，但该专家小组在根据基因型得出治疗建议方面高度一致。
Background. Resistance testing is considered standard of care in HIV medicine, but there is no standard interpretation system for genotype tests. We sought to determine how much agreement exists within a group of experts in the interpretation of complex genotypes.Methods. Genotypes from clinical specimens were sent to an international panel of 12 resistance experts. Phenotypic susceptibility testing of these clinical isolates was performed with antivirogram. Experts predicted phenotype fold change category (<2.5-fold change, 2.5–4.0-fold change, >4.0- to 7.0-fold change, >7.0- to 10-fold change, >10- to 20-fold change, or >20-fold change) and predicted expected drug activity for each of 16 antiretroviral drugs. Experts were also asked to make treatment recommendations on the basis of the genotype.Results. The experts predicted the exact phenotype fold change category correctly 44% of the time, but they varied widely by antiretroviral drug (range, 25%–74%). The highest accuracy was observed for lamivudine (74%) and the nonnucleoside reverse transcriptase inhibitors (66%–69%). Experts generally predicted higher levels of resistance to the remaining nucleoside reverse transcriptase inhibitors than what was found by phenotypic testing. Agreement among experts in predicting phenotype fold change category ranged widely depending on the drug (median agreement, 42% [range, 28%–74%]); the same pattern was observed in predicting expected drug activity (median agreement, 45% [range, 32%–87%]). Experts agreed on treatment recommendations in a median of 79% of instances, and recommendations were consistent over time, with blinded retesting.Conclusions. Although their ability to predict phenotype from a genotype varied for individual antiretroviral drugs, this expert panel had a high degree of agreement in deriving treatment recommendations from the genotype.
登录
查看更多内容
不同系统对抗逆转录病毒治疗结果的可变预测，用于解释基因型人类免疫缺陷病毒 1 型耐药性。
影响因子：
6.4
作者：
A. De Luca;A. Cingolani;S. Di Giambenedetto;M. Trotta;F. Baldini;M. Rizzo;A. Bertoli;G. Liuzzi;P. Narciso;R. Murri;A. Ammassari;C. Perno;A. Antinori
通讯作者：
A. Antinori
HIV 耐药性测试在患者随访中实际应用的实验室指南
影响因子：
1.2
作者：
A. Vandamme;François Houÿez;Dénes Bánhegyi;B. Clotet;G. Schrijver;K. D. Smet;William W. Hall;Richard Harrigan;N. Hellmann;K. Hertogs;C. Holtzer;B. Larder;Deenan Pillay;E. Race;J. Schmit;Rob Schuurman;E. Shulse;A. Sönnerborg;Veronica Miller
通讯作者：
Veronica Miller
从基因型数据预测阿巴卡韦耐药性：齐多夫定和拉米夫定耐药性的体外和体内影响
影响因子：
4.9
作者：
H. Walter;B. Schmidt;M. Werwein;E. Schwingel;K. Korn
通讯作者：
K. Korn
影响因子：
3.8
作者：
Brun-Vézinet, F;Descamps, D;Costagliola, D
通讯作者：
Costagliola, D
一项表型敏感性测试与抗逆转录病毒治疗护理标准的随机前瞻性研究：CCTG 575。
DOI：
--
发表时间：
2005
期刊：
AIDS (London, England)
影响因子：
--
作者：
Haubrich,RichardH;Kemper,CarolA;Hellmann,NicholasS;Keiser,PhilipH;Witt,MalloryD;Tilles,JeremiahG;Forthal,DonaldN;Leedom,John;Leibowitz,Matthew;McCutchan,JAllen;Richman,DouglasD;CaliforniaCollaborativeTreatmentGroup
通讯作者：
CaliforniaCollaborativeTreatmentGroup